What is Leerink Partnrs' Estimate for FULC FY2027 Earnings?

Key Points

• Leerink Partners has revised down its FY2027 earnings per share estimate for Fulcrum Therapeutics to ($1.36), compared to a prior estimate of ($1.17).
• The consensus estimate for Fulcrum Therapeutics' current full-year earnings stands at ($0.16) per share, signaling a significant expected loss.
• Analysts have mixed ratings on Fulcrum Therapeutics, with one rating a Strong Buy, four giving a Buy, one a Hold, and another a Sell.

Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Equities researchers at Leerink Partnrs reduced their FY2027 earnings per share estimates for shares of Fulcrum Therapeutics in a note issued to investors on Tuesday, October 7th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will earn ($1.36) per share for the year, down from their prior forecast of ($1.17). The consensus estimate for Fulcrum Therapeutics' current full-year earnings is ($0.16) per share.

A number of other brokerages have also recently commented on FULC. Weiss Ratings reissued a "sell (d-)" rating on shares of Fulcrum Therapeutics in a research note on Wednesday. Royal Bank Of Canada increased their price target on shares of Fulcrum Therapeutics from $4.00 to $5.00 and gave the company a "sector perform" rating in a research report on Wednesday, July 30th. Wall Street Zen upgraded Fulcrum Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday, September 26th. Finally, HC Wainwright raised Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and upped their target price for the company from $4.00 to $12.00 in a research note on Tuesday, July 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $9.60.

Fulcrum Therapeutics Stock Down 0.1%

Shares of FULC stock opened at $9.62 on Friday. The stock has a market cap of $520.35 million, a P/E ratio of -7.89 and a beta of 2.93. Fulcrum Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $9.88. The business has a fifty day simple moving average of $7.41 and a 200-day simple moving average of $6.28.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01.

Hedge Funds Weigh In On Fulcrum Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Jump Financial LLC acquired a new position in Fulcrum Therapeutics in the 1st quarter worth $30,000. Brooklyn Investment Group lifted its holdings in Fulcrum Therapeutics by 209.7% in the 1st quarter. Brooklyn Investment Group now owns 12,190 shares of the company's stock worth $35,000 after buying an additional 8,254 shares in the last quarter. Virtu Financial LLC acquired a new position in Fulcrum Therapeutics in the 1st quarter worth $39,000. Russell Investments Group Ltd. lifted its holdings in Fulcrum Therapeutics by 4,209.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company's stock worth $64,000 after buying an additional 9,092 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC lifted its holdings in Fulcrum Therapeutics by 26.1% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company's stock worth $89,000 after buying an additional 2,677 shares in the last quarter. Institutional investors and hedge funds own 89.83% of the company's stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.